Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2021 March;63(1) > Panminerva Medica 2021 March;63(1):46-50



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



Panminerva Medica 2021 March;63(1):46-50

DOI: 10.23736/S0031-0808.20.03955-5


lingua: Inglese

Idiopathic myalgic pain (fibromyalgia): supportive management and prevention with Pycnogenol®

Gianni BELCARO 1, 2 , Shu HU 1, 2, Maria R. CESARONE 1, 2, Mark DUGALL 1, Claudia SCIPIONE 1, Valeria SCIPIONE 1, Morio HOSOI 1, Andrea LEDDA 1, Umberto CORNELLI 1, Beatrice FERAGALLI 1, Roberto COTELLESE 1

1 IRVINE3 Labs & San Valentino Vascular Screening Project, Department of Medical, Oral and Biotechnological Sciences, Ch-Pe University, Pescara, Italy; 2 IA-PSS: International Agency for Pharma-Standard Supplements, Pescara, Italy

BACKGROUND: The aim of this registry study was the prospective evaluation of the efficacy of Pycnogenol® in idiopathic fibromyalgia (FM), over 4 weeks in comparison with the standard management (SM).
METHODS: A SM and a Pycnogenol®+SM group were formed. Pycnogenol® supplementation was used at the dose of 150 mg/day (4 weeks). The study considered the most important/frequent symptoms of FM.
RESULTS: Fifty patients with idiopathic fibromyalgia were included: 26 in the Pycnogenol® group and 24 served as controls. The two groups were comparable at inclusion. No other disease or condition was present. All subjects were otherwise healthy women (BMI<26), not using any drug. All subjects had an elevated level of oxidative stress (OS) at inclusion. All routine blood tests - and all inflammatory and rheumatic tests - were within the normal range at inclusion and at the end of the study. No safety or tolerability problems were observed. The percentage of patients using NSAIDs (non-steroidal anti-inflammatory drugs) as rescue medications in the observation period was significantly higher in the SM management group (P<0.05) in comparison with the supplement group. The percentage of patients using corticosteroids as rescue medication was significantly higher in the SM group (P<0.05). The percentage of subjects with the symptoms/complaints decreased significantly, considering each symptom, with Pycnogenol® after 4 weeks in comparison with the SM (P<0.05).
CONCLUSIONS: Pycnogenol® supplementation appears to control and reduce the intensity of common symptoms and complaints - especially pain-related - associated with FM. Pycnogenol® could be a ‘soft’, safe supplementation and prevention method to manage the symptoms of most of these patients, even for longer periods, reducing the need for drugs.

KEY WORDS: Pycnogenols; Fibromyalgia; Fatigue; Oxidative stress; Prevention and control

inizio pagina